

Can pyrethroid-piperonyl butoxide (PBO) nets reduce the efficacy of indoor residual spraying with pirimiphos-methyl against pyrethroid-resistant malaria vectors?

Authors: Thomas Syme^{1,2,3}, Martial Gbegbo^{2,3}, Dorothy Obuobi^{1,2,3}, Augustin Fongnikin^{2,3}, Abel Agbevo^{2,3}, Damien Todjinou^{2,3}, Corine Ngufor^{1,2,3*}

Affiliations:

¹London School of Hygiene & Tropical Medicine, United Kingdom

²Centre de Recherche Entomologique de Cotonou, Benin

³Pan African Malaria Vector Research Consortium (PAMVERC), Benin

Keywords: Malaria, vector control, Anopheles, long-lasting insecticidal nets, indoor residual spraying, pyrethroid, piperonyl butoxide, organophosphate, carbamate, insecticide treated nets, pyrethroid-PBO, pirimiphos-methyl, Actellic, Olyset Plus, PermaNet 3.0, bendiocarb, insecticide resistance, antagonism, mixtures, combinations.

*Corresponding author

Email: corine.ngufor@lshtm.ac.uk

Short Title: Combining PBO nets with pirimiphos-methyl IRS

Abstract

As the uptake of pyrethroid-PBO ITNs increases, their combination with IRS insecticides could become an operational reality in many malaria-endemic communities. Pirimiphos-methyl is a pro-insecticide requiring activation by mosquito cytochrome P450 enzymes to induce toxicity while PBO blocks activation of these enzymes in pyrethroid-resistant vector mosquitoes. PBO may thus antagonise the toxicity of pirimiphos-methyl IRS when combined with pyrethroid-PBO ITNs. The impact of combining two major brands of pyrethroid-PBO ITNs (Olyset® Plus, PermaNet® 3.0) with pirimiphos-methyl IRS (Actellic® 300CS) was evaluated against pyrethroid-resistant *Anopheles gambiae* sl in two parallel experimental hut trials in southern Benin in comparison to bendiocarb IRS and each intervention alone. The wild vector population was resistant to pyrethroids but susceptible to pirimiphos-methyl and bendiocarb. PBO pre-exposure partially restored deltamethrin toxicity but not permethrin. Mosquito mortality in experimental huts was significantly improved in the combinations of bendiocarb IRS with Olyset® Plus (33%) and PermaNet® 3.0 (38%) compared to bendiocarb IRS alone (14–16%, $p < 0.001$), demonstrating an additive effect. Conversely, mortality was significantly reduced in the combinations of pirimiphos-methyl IRS with Olyset® Plus (59%) and PermaNet® 3.0 (55%) compared to pirimiphos-methyl IRS alone (77–78%, $p < 0.001$), demonstrating an antagonistic effect. Combining pirimiphos-methyl IRS with the pyrethroid-PBO ITNs provided significantly improved mosquito mortality (55–59%) compared to the pyrethroid-PBO ITNs alone (22–26%) and improved blood-feeding inhibition relative to the IRS alone. This study provided evidence of an antagonistic effect when pyrethroid-PBO ITNs were combined with pirimiphos-methyl IRS in the same household resulting in lower levels of vector mosquito mortality compared to the IRS alone. Pirimiphos-methyl IRS also showed potential to significantly enhance malaria control when deployed to complement pyrethroid-PBO ITNs in an area where PBO fails to fully restore susceptibility to pyrethroids.

Introduction

The large-scale implementation of long-lasting insecticidal nets (LLINs), and indoor residual spraying (IRS) has resulted in profound reductions in malaria-associated morbidity and mortality across sub-Saharan Africa, over the last two decades [1]. Unfortunately, resistance to the insecticides applied through these interventions, especially the pyrethroids, is now pervasive in vector populations in malaria-endemic countries [2], threatening to undermine the impact of these interventions. In response, a new generation of novel LLINs and IRS based on new active ingredients with the potential to sustain vector control impact in the face of increasing resistance, have been developed [3]. This includes dual insecticide-treated nets containing a pyrethroid and an alternative effective new compound as well as new IRS insecticides with novel modes of action or improved formulations that have shown potential to provide enhanced control of insecticide-resistant malaria vector populations.

Insecticide-treated nets (ITNs) combining a pyrethroid and piperonyl butoxide (PBO) were the first novel class of ITNs to be developed for malaria vector control. PBO is a synergist that can enhance the impact of pyrethroids and other insecticides by inhibiting metabolic detoxification enzymes associated with resistance, namely cytochrome P450 monooxygenases [4]. These nets received a conditional endorsement from the World Health Organisation (WHO) in 2017 based on results from a cluster-randomised controlled trial in Tanzania demonstrating a reduction in malaria prevalence in communities allocated to pyrethroid-PBO ITNs relative to pyrethroid-only ITNs [5, 6]. A full policy recommendation is now expected after results from a second CRT in Uganda also showed that two brands of pyrethroid-PBO ITNs reduced malaria prevalence relative to pyrethroid-only nets [7]. The WHO endorsement and expanding evidence base for the public health value of pyrethroid-PBO ITNs has prompted mass procurement of these nets by international malaria control agencies [8, 9]. The proportion of pyrethroid-PBO ITNs of all ITNs delivered in sub-Saharan Africa has consequently risen from 3% in 2018 to 35% in 2021 [10]; pyrethroid-PBO ITNs are therefore replacing pyrethroid-only nets in many malaria-endemic countries.

The increasing distribution and intensity of pyrethroid resistance has also affected malaria control policy regarding insecticide choice for IRS over the last decade. To improve vector control impact and preserve pyrethroids for ITNs, African IRS programmes partly suspended the use of pyrethroids and organochlorines in favour of carbamates and organophosphates [11, 12]. Whilst both insecticides showed high toxicity against malaria vectors, the short residual duration of the initial formulations approved for IRS proved prohibitive, necessitating the development of longer-lasting formulations [13]. A new microencapsulated formulation of pirimiphos-methyl was later developed (Actellic® 300CS) demonstrating prolonged activity against pyrethroid-resistant malaria vector mosquitoes, lasting up to 9 months [14, 15]. This formulation subsequently served as the insecticide of choice for the majority of IRS programmes in sub-Saharan Africa [13] providing substantial control of mosquito vectors and malaria across distinct eco-epidemiological settings [6, 16-22].

Where resources are available, there is opportunity to deploy LLINs together with IRS in the same geographical location as a combined intervention approach. The combined LLIN and IRS intervention approach presents opportunities to improve vector control impact by providing multiple chances to target the vector and manage insecticide resistance by presenting two or more insecticides to the vector at the same time. The impact of this approach however depends on several factors including the local vector characteristics and the mode of action of the insecticides involved and interactions that may exist between them [23]. As the uptake of pyrethroid-PBO ITNs increases, their combination with IRS insecticides such as pirimiphos-methyl could become an operational reality in

many malaria-endemic communities. Pirimiphos-methyl is a pro-insecticides requiring activation by mosquito enzymes (cytochrome P450 enzymes) to induce toxicity [24]. In mosquitoes with elevated cytochrome P450 enzymes, this activation process will occur faster. By contrast, PBO is combined with pyrethroids on ITNs to enhance the mortality of pyrethroid-resistant vector mosquitoes by inhibiting the activity of these enzymes. It has therefore been hypothesised that the inhibitory action of PBO against cytochrome P450 enzymes may antagonise the toxicity of pro-insecticides like pirimiphos-methyl when used for IRS in combination with pyrethroid-PBO ITNs [25]. Indeed, previous studies on aquatic fleas showed that coadministration of PBO effectively reduced the acute toxicity of organophosphate insecticides requiring metabolic activation by cytochrome P450 but did not affect the toxicity of insecticides not requiring such metabolic activation [26]. Another study assessing the role of PBO in the metabolism of the organophosphorus insecticide, chlorpyrifos in two aquatic invertebrate species also demonstrated that PBO reduced toxicity to the insecticide via cytochrome P450 mediated reactions [27]. Though evidence of this antagonism between PBO and organophosphate insecticides is yet to be demonstrated in bioassays with mosquito vectors of malaria, there have been reports indicating negative interactions in *Anopheles* and *Culex* mosquitoes in bioassays with PBO and other insecticides used for malaria vector control that require metabolic activation [28-30]. A community randomised controlled trial in Tanzania demonstrated a redundant effect on malaria prevalence when adding pirimiphos-methyl IRS in communities with high coverage of pyrethroid-PBO ITNs however, it is not clear whether there was antagonism between the ITNs and IRS [6]. Given the increasing uptake of pyrethroid-PBO ITNs, controlled empirical studies are required, to demonstrate how they interact with different types of IRS and the potential advantages and disadvantages of combining these interventions against different vector populations. Data generated from such trials can be used to inform malaria control policy in areas where the combined implementation of these interventions is anticipated.

In this study, we evaluated the impact of combining two major types of WHO-prequalified pyrethroid-PBO ITNs that have demonstrated additional public health benefit compared to pyrethroid-only nets (Olyset® Plus and PermaNet® 3.0) with IRS using pirimiphos-methyl (Actellic® 300CS) in comparison to bendiocarb IRS in experimental hut trials in a pyrethroid resistance area of southern Benin. The combinations were also compared to each intervention alone.

Results

Study site and experimental hut treatments

Experimental huts are used to assess the capacity of indoor vector control interventions to prevent wild vector mosquito entry and feeding and induce early mosquito exiting and mortality when applied in a human-occupied house, under carefully controlled conditions [31, 32]. The hut trials were conducted at the CREC/LSHTM experimental hut station in Covè, southern Benin (7°14'N2°18'E), situated in a vast area of rice irrigation, which provides extensive and permanent breeding sites for mosquitoes. The rainy season extends from March to October and the dry season from November to February. *Anopheles coluzzii* and *An. gambiae* sensu stricto (s.s.) occur in sympatry, with the latter present at lower densities and predominantly in the dry season. The vector population is susceptible to organophosphates and carbamates but exhibits intense resistance to pyrethroids (200-fold). Molecular genotyping and microarray studies have demonstrated a high frequency of the knockdown resistance L1014F allele (>90%) and overexpression of CYP6P3, an enzyme associated with pyrethroid detoxification [33].

Two experimental hut trials were performed in parallel for 4 months between April and July 2020. Trial 1 assessed the impact of combining Olyset® Plus (Sumitomo Chemical), a permethrin-based pyrethroid-PBO ITN with pirimiphos-methyl IRS while Trial 2 assessed the impact of combining PermaNet® 3.0 (Vestergaard Sarl), a deltamethrin-based pyrethroid-PBO ITN with pirimiphos-methyl IRS.

The following six treatments were tested in each of the experimental hut trials:

Trial 1:

1. Untreated net
2. Olyset® Plus (Sumitomo Chemical)
3. Bendiocarb IRS applied at 400 mg/m² (Ficam® 80WP, Bayer)
4. Olyset® Plus + Bendiocarb IRS applied at 400 mg/m²
5. Pirimiphos-methyl IRS applied at 1000 mg/m² (Actellic® 300CS, Syngenta)
6. Olyset® Plus + Pirimiphos-methyl IRS applied at 1000 mg/m²

Trial 2:

1. Untreated net
2. PermaNet® 3.0 (Vestergaard Sarl)
3. Bendiocarb IRS applied at 400 mg/m² (Ficam® 80WP, Bayer)
4. PermaNet® 3.0 + Bendiocarb IRS applied at 400 mg/m²
5. Pirimiphos-methyl IRS applied at 1000 mg/m² (Actellic® 300CS, Syngenta)
6. PermaNet® 3.0 + Pirimiphos-methyl IRS applied at 1000 mg/m²

Olyset® Plus and PermaNet® 3.0 are WHO prequalified pyrethroid-PBO ITNs [3]. Olyset® Plus is made of polyethylene filaments coated with 20 g/Kg of permethrin and 10 g/Kg of PBO. PermaNet® 3.0 consists of polyester side panels coated with deltamethrin at 2.1 g/kg and a polyethylene roof panel incorporating deltamethrin and PBO at 4.0 g/kg and 25 g/kg respectively.

Susceptibility of wild vector mosquitoes at Covè to insecticides

WHO susceptibility bioassays were conducted in parallel to the experimental hut trial to determine the susceptibility of the vector population at the Covè hut site to the constituent insecticides of the experimental hut treatments. Mortality rates of F1 progeny of field-collected *An. gambiae* s.l. from the Covè hut station following exposure to discriminating doses of deltamethrin and permethrin in WHO cylinder bioassays were low (42% and 11% respectively), confirming a high frequency of pyrethroid resistance in the Covè vector population (Table 1). Pre-exposure to PBO significantly improved mortality with deltamethrin (42% vs. 72%) but not with permethrin (11% vs. 8%). Mortality rates with the discriminating doses of bendiocarb and pirimiphos-methyl were 96% and 99% respectively demonstrating susceptibility to both insecticides. All insecticides induced 100% mortality with the laboratory-maintained, insecticide-susceptible *An. gambiae* s.s. Kisumu strain. No mortality was recorded in the control with either strain.

Table 1: WHO susceptibility bioassay results with *Anopheles gambiae* sensu lato from Covè. Mosquitoes were exposed to the discriminating doses of deltamethrin (0.05%), permethrin (0.75%), bendiocarb (0.1%) and pirimiphos-methyl (0.25%) in four batches of 20–25 per cylinder. The Covè strain was compared with the laboratory-maintained, susceptible *Anopheles gambiae* sensu stricto Kisumu strain.

Treatment	Strain	N exposed	N dead	% Mortality	95% CIs
Control	Kisumu	96	0	0	–
	Covè	98	3	3	0–7
PBO (4%)	Covè	94	0	0	–
Deltamethrin (0.05%)	Kisumu	94	94	100	–
	Covè	90	38	42	32–52
PBO (4%) + Deltamethrin (0.05%)	Covè	96	69	72	63–81
Permethrin (0.75%)	Kisumu	91	91	100	–
	Covè	85	9	11	4–17
PBO (4%) + Permethrin (0.75%)	Covè	85	7	8	2–14
Bendiocarb (0.1%)	Kisumu	88	88	100	–
	Covè	94	90	96	92–100
Pirimiphos-methyl (0.25%)	Kisumu	98	98	100	–
	Covè	100	99	99	97–100

Experimental hut results

Combining pirimiphos-methyl IRS with pyrethroid-PBO ITNs reduces mosquito entry and enhances early exiting.

A total of 5,404 wild female *An. gambiae* s.l. were collected in the experimental huts over the 4-month trials (Table 2). In both trials, mosquito entry in huts with the pyrethroid-PBO ITNs alone and IRS alone did not differ significantly from the controls ($p > 0.05$) but was significantly reduced with the pyrethroid-PBO ITN plus IRS combinations compared to the single treatments ($p < 0.01$). Mosquito entry rates did not also differ between the combinations of the pyrethroid-PBO ITN with bendiocarb IRS relative to the combinations with pirimiphos-methyl IRS ($p < 0.05$). Nevertheless, IRS treatments could not be rotated and thus, treatment-induced deterrence cannot be fully distinguished from differential attractiveness due to hut position.

The proportion of mosquitoes exiting into the veranda of the huts with the untreated net controls was 36% and 39% for Trials 1 and 2 respectively. Exiting rates were higher with the pyrethroid-PBO ITNs alone (76%) relative to the IRS insecticides alone (51–63% with bendiocarb and 53–69% with pirimiphos-methyl IRS, $P < 0.005$). In both trials, the highest levels of mosquito exiting were achieved with the pyrethroid-PBO ITN plus IRS combinations (79% with bendiocarb and 87–89% with pirimiphos-methyl IRS). Between the combinations, adding pirimiphos-methyl IRS to the pyrethroid-PBO ITN provided significantly higher levels of mosquito exiting relative to adding bendiocarb IRS (87–89% vs. 79%, $P < 0.05$).

Table 2: Entry and exiting of wild, pyrethroid-resistant *Anopheles gambiae* sensu lato in experimental huts in Covè, southern Benin treated with pyrethroid-PBO ITNs and pirimiphos-methyl IRS applied alone and in combination. Results are presented separately for the trials involving Olyset® Plus (Trial 1) and PermaNet® 3.0 (Trial 2).

Treatment	Total females caught*	% Deterrence	Total exiting	% Exophily*	95% CIs
Trial 1					
Untreated net	664 ^a	–	241	36 ^a	33–40
Olyset Plus	511 ^a	23	390	76 ^b	73–80
Bendiocarb IRS	556 ^a	16	282	51 ^c	47–55
Olyset Plus + Bendiocarb IRS	288 ^b	57	228	79 ^b	75–84
P-methyl IRS	531 ^a	20	281	53 ^c	49–57
Olyset Plus + P-methyl IRS	304 ^b	54	270	89 ^d	85–92
Trial 2					
Untreated net	581 ^u	–	226	39 ^u	35–43
PermaNet 3.0	488 ^u	16	369	76 ^v	72–79
Bendiocarb IRS	575 ^u	1	360	63 ^w	59–67
PermaNet 3.0 + Bendiocarb IRS	233 ^v	60	185	79 ^v	74–85
P-methyl IRS	450 ^u	23	311	69 ^x	65–73
PermaNet 3.0 + P-methyl IRS	223 ^v	62	195	87 ^y	83–92

*For each trial, values on this column sharing a superscript letter do not differ significantly.

Combining pirimiphos-methyl IRS with pyrethroid-PBO ITNs reduces mosquito feeding relative to the IRS alone

Blood-feeding rates in huts with the untreated net controls were 72% and 67% for Trials 1 and 2 respectively (Table 3). The IRS treatments did not provide any blood-feeding inhibition relative to the controls. Blood-feeding inhibition rates were high with the pyrethroid-PBO ITN plus IRS combinations in both trials (69-79% with Olyset® Plus and 63-66% with PermaNet® 3.0) and this was generally similar to what was observed with the pyrethroid-PBO ITNs alone (67% with Olyset® Plus and 65% with PermaNet®) showing that the high levels of blood-feeding inhibition in the combinations, was mostly due to the ITNs. Blood-feeding inhibition with the PermaNet® 3.0 plus pirimiphos-methyl IRS combination (66%) was similar to the PermaNet® 3.0 plus bendiocarb IRS combination (63%, $p=0.71$) meanwhile the Olyset® Plus and pirimiphos-methyl IRS combination induced higher levels of blood-feeding inhibition compared to the Olyset® Plus and bendiocarb IRS combination (79% vs. 69%, $p=0.036$). Personal protection levels showed a similar trend and were also higher with the combinations (86-90%) relative to the IRS alone (-33 -13%)

Table 3: Blood-feeding results of wild, pyrethroid-resistant *Anopheles gambiae* sensu lato exposed to pyrethroid-PBO ITNs and pirimiphos-methyl IRS applied alone and in combination in experimental huts in Covè, southern Benin. Results are presented separately for the trials involving Olyset® Plus (Trial 1) and PermaNet® 3.0 (Trial 2).

Treatment	Total Females Caught	Total blood-fed	% Blood-feeding*	95% CIs	% Blood-feeding inhibition	% Personal protection
Trial 1						
Untreated net	664	481	72 ^a	69–76	–	–
Olyset Plus	511	122	24 ^b	20–28	67	75
Bendiocarb IRS	556	528	95 ^c	93–97	-31	-10
Olyset Plus + Bendiocarb IRS	288	64	22 ^b	17–27	69	87
P-methyl IRS	531	420	79 ^d	76–83	-9	13
Olyset Plus + P-methyl IRS	304	47	16 ^e	11–20	79	90
Trial 2						
Untreated net	581	391	67 ^u	64–71	–	–
PermaNet 3.0	488	115	24 ^v	20–27	65	71
Bendiocarb IRS	575	519	90 ^w	88–93	-34	-33
PermaNet 3.0 + Bendiocarb IRS	233	54	23 ^v	18–29	66	86
P-methyl IRS	450	406	90 ^w	88–93	-34	-4
PermaNet 3.0 + P-methyl IRS	223	55	25 ^v	19–30	63	86

*For each trial, values on this column sharing a superscript letter do not differ significantly.

Combining pirimiphos-methyl IRS with pyrethroid-PBO ITNs reduces mosquito mortality relative to the IRS alone.

Wild vector mosquito mortality in the controls was 3% in Trial 1 and 2% in Trial 2 (Table 4). The pyrethroid-PBO ITNs killed relatively low mosquito proportions (22% with Olyset® Plus and 26% with PermaNet® 3.0) though this was higher than what was observed with bendiocarb IRS alone (14 in Trial 1 and 16% in Trial 2, $P < 0.01$). The highest mortality was achieved with pirimiphos-methyl IRS alone (77% in Trial 1 and 78% in Trial 2). In both trials, mortality in the pyrethroid-PBO ITN plus pirimiphos-methyl IRS combinations was significantly reduced compared to pirimiphos-methyl IRS alone (77% with pirimiphos-methyl IRS vs. 59% with Olyset® Plus plus pirimiphos-methyl IRS, $p < 0.001$ and 78% with pirimiphos-methyl IRS vs. 55% with PermaNet® 3.0 plus pirimiphos-methyl IRS, $p < 0.001$), demonstrating an antagonistic effect. Conversely, mortality was significantly higher in the combinations of bendiocarb IRS with Olyset® Plus (33%) and PermaNet® 3.0 (38%) than bendiocarb IRS alone (14–16%, $p < 0.001$), demonstrating an additive effect (Table 4). Nevertheless, both pyrethroid-PBO plus IRS combinations induced significantly higher mortality compared to the pyrethroid-PBO ITNs alone ($p < 0.001$). Between the combinations, mortality was consistently higher with the pyrethroid-PBO ITN plus pirimiphos-methyl IRS combinations (55–59%) compared to the pyrethroid-PBO ITN plus bendiocarb IRS (33–39%, $p < 0.001$).

The monthly mortality rates of wild vector mosquitoes which entered the experimental huts during the trials are presented in Fig 1 for the combinations with bendiocarb IRS and Fig 2 for the combinations with pirimiphos-methyl IRS. In both trials, mosquito mortality rates in huts with the pyrethroid-PBO ITNs plus bendiocarb IRS declined sharply over time from 65–75% in month 1 to 33–38% in month 3, nevertheless, it was consistently higher than the single treatments alone (Fig 1). Mosquito mortality in the combination of Olyset® Plus plus pirimiphos-methyl IRS was similar to the IRS alone in month 1 (>90%) but declined substantially relative to the IRS in subsequent months.

With the PermaNet® 3.0 plus pirimiphos-methyl IRS combination, mosquito mortality was consistently lower than the IRS alone throughout the trial. Through the four months of the trials, the pyrethroid-PBO ITN plus pirimiphos-methyl IRS combinations consistently induced higher levels of mosquito mortality relative to the pyrethroid-PBO ITNs alone.

Table 4: Mortality results of wild, pyrethroid-resistant *Anopheles gambiae* sensu lato in experimental huts in Covè, southern Benin treated with pyrethroid-PBO ITNs, and pirimiphos-methyl IRS applied alone and in combination. Results are presented separately for the trials involving Olyset® Plus (Trial 1) and PermaNet® 3.0 (Trial 2).

Treatment	Total Females Caught	Total dead	% Mortality*	95% CIs
Trial 1				
Untreated net	664	22	3 ^a	2–5
Olyset Plus	511	114	22 ^b	19–26
Bendiocarb IRS	556	87	16 ^c	13–19
Olyset Plus + Bendiocarb IRS	288	95	33 ^d	28–38
P-methyl IRS	531	411	77 ^e	74–81
Olyset Plus + P-methyl IRS	304	178	59 ^f	53–64
Trial 2				
Untreated net	581	12	2 ^u	1–3
PermaNet 3.0	488	127	26 ^v	22–30
Bendiocarb IRS	575	80	14 ^w	11–17
PermaNet 3.0 + Bendiocarb IRS	233	89	38 ^x	32–44
P-methyl IRS	450	350	78 ^y	74–82
PermaNet 3.0 + P-methyl IRS	223	122	55 ^z	48–61

*For each trial, values on this column sharing a superscript letter do not differ significantly.




Fig 1: Monthly mortality rates of wild, pyrethroid-resistant *Anopheles gambiae* sensu lato entering experimental huts with pyrethroid-PBO ITNs and bendiocarb IRS, applied alone and in combination in Covè, southern Benin. Panel a presents results from the trial with Olyset® Plus (Trial 1) and panel b presents results from the trial with PermaNet® 3.0 (Trial 2). Error bars represent 95% CIs. Monthly mortality rates are cumulated with increasing time elapsed from onset of the trial.




Fig 2: Monthly mortality rates of wild, pyrethroid-resistant *Anopheles gambiae* sensu lato entering experimental huts with pyrethroid-PBO ITNs and pirimiphos-methyl IRS, applied alone and in combination in Covè, southern Benin. *Panel a presents results from the trial with Olyset® Plus and panel b presents results from the trial with PermaNet® 3.0.* Error bars represent 95% CIs. Monthly mortality rates are cumulated with increasing time elapsed from the onset of the trial.

Tunnel test bioassays

To further assess the efficacy of the pyrethroid-PBO ITNs and help explain the findings in the experimental huts, tunnel tests were performed using the susceptible *An.gambiae* Kisumu strain and pyrethroid-resistant *An. gambiae* sl from Covè on net samples (30x30cm) obtained from Olyset® Plus and PermaNet® 3.0 nets. The tunnel test is an overnight animal baited bioassay that simulates host-seeking behaviour of vector mosquitoes under controlled laboratory conditions. Both pyrethroid-PBO ITNs were compared to pyrethroid-only nets which contained similar pyrethroid-insecticides (Olyset® Net and PermaNet® 2.0). Mortality in the control tunnels was 11% with the susceptible Kisumu strain and 2% with the pyrethroid-resistant Covè strain. All ITN types induced >98% mortality with the susceptible Kisumu strain. Olyset® Plus killed significantly higher proportions of the Covè mosquitoes compared to Olyset® Net (90% vs. 42%). With PermaNet® 3.0, mortality of Covè mosquitoes exposed to netting pieces obtained from the PBO treated roof of the net (68%) was higher compared to net pieces obtained from the sides of the net (34%) and PermaNet® 2.0 (27%). The results, therefore, showed higher levels of mortality against pyrethroid-resistant mosquitoes from the Covè experimental hut station with the pyrethroid-PBO ITNs relative to pyrethroid-only nets. More detailed results from the tunnel tests are available in the supplementary information (Table S1).




Fig 3: Mortality (24h) of susceptible *Anopheles gambiae* Kisumu and pyrethroid-resistant *An. gambiae* s.l. Covè strains exposed to Olyset® Plus and PermaNet® 3.0 in tunnel tests. Error bars represent 95% CIs. Both pyrethroid-PBO nets were compared to pyrethroid-only nets (Olyset® Net and PermaNet® 2.0). PermaNet® 3.0 contains PBO only on the roof of the net. With both strains, 80–120 mosquitoes were exposed overnight to netting pieces cut from whole nets in 2–3 replicate tunnel tests.

Wall cone bioassays

WHO wall cone bioassays were performed on the IRS treated experimental hut walls 1 week, 2 months and 4 months after application of IRS treatments to assess their residual efficacy with increasing time elapsed from spraying. Mortality rates of the insecticide-susceptible *An. gambiae* s.s. Kisumu strain and pyrethroid-resistant *An. gambiae* s.l. Covè strain following exposure to IRS-treated surfaces in 30 min wall cone bioassays are presented in Fig 4. Mortality of mosquitoes exposed to pirimiphos-methyl treated walls was high (>90%) at all time points with both strains, showing no evidence of a decline in residual activity. In contrast, wall cone bioassay mortality on bendiocarb-treated surfaces declined rapidly, beginning at 67% and 39% in week 1 and falling to lows of 2% and 3% in month 4 with the Kisumu and Covè strains respectively. No mortality was recorded in the controls at any time point with either strain.




Fig 4: Mortality (24 h) of insecticide-susceptible *Anopheles gambiae* sensu stricto Kisumu strain and pyrethroid-resistant *Anopheles gambiae* sensu lato Covè strain exposed to treated experimental hut walls in 30 min wall cone bioassays. Error bars represent 95% CIs. Approximately 50, 3–5-day old mosquitoes of each strain were exposed to treated walls for 30 mins in 5 batches of 10, 1 week 2 months and 4 months after application of treatments. Mortality was recorded after 24 h.

Discussion

As the uptake of pyrethroid-PBO ITNs continues to rise, their combined use with IRS could become an operational reality in many malaria-endemic settings across Africa. Given the inhibitory effect of PBO on mosquito cytochrome P450 enzymes, the WHO had temporarily recommended against the use of pyrethroid-PBO ITN in areas programmed for IRS with pirimiphos-methyl IRS until further evidence on the potential antagonism between PBO and the organo-thiophosphate pro-insecticide becomes available [25]. In this study, we found evidence of an antagonistic effect when pyrethroid PBO ITNs were combined with pirimiphos-methyl IRS in the same household in a pyrethroid-resistant area in Southern Benin where resistance was partly conferred by over-expression of mosquito cytochrome P450 enzymes [33]. Unlike the combination of the pyrethroid-PBO nets with bendiocarb IRS which provided improved vector mosquito mortality compared to bendiocarb IRS alone, combining these nets with pirimiphos-methyl IRS induced significantly lower levels of vector mosquito mortality rates compared to pirimiphos-methyl IRS alone. This effect was remarkably similar between the two brands of pyrethroid-PBO ITNs tested across both hut trials indicating that the negative interaction of the combination on mosquito mortality was less affected by the design and specifications of the pyrethroid-PBO ITN. Wild vector mosquitoes which entered the huts with the combined treatment may have contacted the pirimiphos-methyl IRS on the hut wall only after picking up PBO from the ITN while attempting to blood-feed on the sleeper under the net. This pre-exposure to PBO on the ITN could have prevented the metabolic activation of the IRS insecticide in these mosquitoes, resulting in lower mortality rates relative to the IRS alone. This finding supports WHO's recommendation against the deployment of pyrethroid-PBO ITNs in areas that have already been programmed for IRS with pirimiphos-methyl IRS. This is mostly important from a programmatic perspective where a vector control programme is faced with multiple choice of ITN types to deploy as an additional intervention to enhance vector control impact in an area that is already dedicated to IRS with pirimiphos-methyl. In such a scenario, other types of ITNs like pyrethroid-only nets which were recently shown to complement pirimiphos-methyl IRS when applied together [23], should be considered.

These findings should however not be interpreted to mean that pirimiphos-methyl IRS must not be deployed to complement pyrethroid-PBO ITNs. Though pyrethroid-PBO ITNs have consistently shown improved performance in experimental hut trials against pyrethroid-resistant malaria vectors compared to pyrethroid-only nets [34], the margin appears to vary depending on the intensity and mechanisms of pyrethroid-resistance encountered. In our study, the pyrethroid-PBO ITNs when applied alone in a hut induced low vector mosquito mortality (22-26%) compared to what has been observed in hut trials against the same vector population with another type of novel dual ITN (71-76%) [35, 36]. Similar levels of hut mortality rates with pyrethroid-PBO ITNs (<30%) and failure of PBO to fully restore pyrethroid susceptibility in bioassays has also been reported from studies in Burkina Faso [37], Cameroon [38], Côte d'Ivoire [39] and Senegal [40]. This may indicate the presence of complex resistance mechanisms in the West African region unaffected by PBO. Compared to East Africa, West Africa has shown historically higher intensity of pyrethroid resistance in malaria vectors which continues to increase over time [41], yet the public health value of pyrethroid-PBO ITNs has not been assessed in the region. It is therefore unclear whether these nets will provide the same improved epidemiological impact over pyrethroid-only nets in West Africa as observed in the East African community trials which have been the basis of their endorsement for malaria control. Our results showed a significant improvement in mosquito mortality when pirimiphos-methyl IRS was combined with the pyrethroid-PBO ITNs (55-59%) compared to the pyrethroid-PBO ITNs alone (22-26%). Mosquito entry and feeding rates were also significantly lower

with the combination compared to the pyrethroid-PBO ITNs alone. This provides some justification for deploying pirimiphos-methyl IRS to complement pyrethroid-PBO nets in an area of high and complex pyrethroid-resistance where local vectors are less susceptible to the synergistic effect of PBO. Due to the limited choice of insecticides available for IRS, where a beneficial effect of the combination compared to the pyrethroid-PBO ITN alone has been established, pirimiphos-methyl IRS should continue to be used even in the presence of high coverage with pyrethroid-PBO ITNs, preferably as part of an IRS rotational strategy. In line with WHO recommendations for insecticide resistance management [42], the sustained rotation of multiple insecticide modes of action for IRS may help preserve efficacy to insecticides approved for IRS.

Considering the significant increase in mosquito mortality with the combination compared to the pyrethroid-PBO ITN alone in our study, it is unclear whether the redundant effect of adding pirimiphos-methyl IRS to pyrethroid-PBO ITNs on clinical malaria observed in the community randomised trial in Tanzania [6] applies to other settings. Unlike our study which showed no restoration of susceptibility to permethrin in bioassays following pre-exposure to PBO, restoration of susceptibility to permethrin - the pyrethroid insecticide used on the pyrethroid-PBO ITN tested in the Tanzanian trial (Olyset® Plus) - was substantially high in the vector population from the study area (from 18% to 94%) [43]. Hence, the level of control achieved with pyrethroid-PBO ITN alone in the Tanzanian trial may have been optimal making the addition of pirimiphos-methyl IRS unnecessary. This may not be the case in many communities in West Africa considering the aforementioned low levels of pyrethroid-PBO synergism reported in susceptibility bioassays and hut trials conducted across the region; in contrast, the addition of pirimiphos-methyl IRS to pyrethroid-PBO ITNs in these communities could be more beneficial for control of clinical malaria compared to the ITN alone. As the range of vector control products available to vector control programmes expands, the choice of interventions and product brands must be aligned to local contexts and guided by local evidence. To help guide vector control policy, epidemiological trials and/or other empirical studies investigating the impact and cost-effectiveness of pyrethroid-PBO nets in communities in the West African region as well as their combination with IRS using pro-insecticides like pirimiphos-methyl will be necessary.

Although the inhibitory effect of PBO on mosquito cytochrome P450 enzymes formed the basis of our hypothesis for the antagonism observed between pirimiphos-methyl IRS and pyrethroid-PBO ITNs in the experimental huts, behavioural interactions could also have contributed. In both trials, mosquito exiting rates into the veranda traps and blood-feeding inhibition were consistently higher in the combinations compared to the IRS insecticides alone. This could be attributed to the excito-repellent property of the pyrethroid in the ITN stimulating directed movement of mosquitoes away from their source [44]. This early exiting effect was however significantly higher in the combination with pirimiphos-methyl IRS compared to the combination with bendiocarb IRS suggesting a behavioural interaction in the presence of pirimiphos-methyl that may have driven more mosquitoes to exit into the veranda, thus reducing mosquitoes' contact with pirimiphos-methyl IRS treated walls. This may have compromised the impact of the pirimiphos-methyl IRS in the combination compared to when applied alone and to the combination with bendiocarb. Further studies to assess mosquito flight behaviour, in the presence of the combinations would provide useful insight into behavioural interactions between the treatments. Controlled laboratory assays which minimise behavioural responses and assess P450 enzyme activity in exposed mosquitoes, could also elucidate the potential role of P450 enzyme inhibition in the antagonism observed in the experimental huts.

While our trial focused on investigating the impact of combining pyrethroid-PBO ITNs with pirimiphos-methyl IRS in the same households, there is a paucity of information on the interactions

between these nets and other newly developed vector control products which contain new public health insecticides such as the neonicotinoid, clothianidin and the pyrrole chlorfenapyr. Chlorfenapyr, an insecticide used on ITNs [35] and being considered for IRS [45, 46], also requires activation by mosquito P450 enzymes [47]. Laboratory experiments have indicated the potential of PBO to antagonise the toxicity of chlorfenapyr against mosquitoes in bioassays [29, 30]. Studies investigating the impact of co-deploying pyrethroid-PBO ITNs together with pyrethroid-chlorfenapyr ITNs or chlorfenapyr IRS in the same household will be essential to help inform optimal co-deployment policy.

Conclusion

Our study provides the first evidence of an antagonistic effect when pyrethroid-PBO ITNs are combined with pirimiphos-methyl IRS in the same household resulting in lower levels of vector mosquito mortality compared to the IRS alone. In line with WHO recommendations, vector control programmes faced with multiple choice of ITN types to deploy as an additional intervention to improve vector control impact in an area dedicated to IRS with pirimiphos-methyl, may consider other types of ITNs like pyrethroid-ITNs which can better complement pirimiphos-methyl IRS when deployed together. Nevertheless, the pyrethroid-PBO ITNs performed poorly probably due to the lower levels of restoration of pyrethroid susceptibility with PBO in the vector population. Combining these nets with pirimiphos-methyl IRS provided significantly improved vector control compared to the net alone demonstrating the potential for pirimiphos-methyl IRS to enhance malaria control when deployed to complement pyrethroid-PBO ITNs in areas where PBO fails to fully restore susceptibility to pyrethroids.

Materials and methods

WHO susceptibility bioassays

Adult F1 progeny of field-collected *An. gambiae* s.l. from the Covè hut station were exposed to filter papers treated with discriminating doses of deltamethrin (0.05%), permethrin (0.75%), bendiocarb (0.1%) and pirimiphos-methyl (0.25%) in WHO cylinders [48]. Deltamethrin and permethrin were also tested with 60 mins pre-exposure to PBO (4%) to assess the involvement of metabolic enzymes in pyrethroid resistance. A comparison was made with the laboratory-maintained, susceptible *An. gambiae* s.s. Kisumu strain. Approximately 100, 3–5-day old mosquitoes of each strain were exposed to each insecticide for 60 mins in four batches of 20–25. Similar numbers of mosquitoes were concurrently exposed to untreated filter papers as a control. At the end of exposure, mosquitoes were transferred to appropriately labelled holding tubes, provided access to 10% (w/v) glucose solution and held at $27\pm2^{\circ}\text{C}$ and $75\pm10\%$ relative humidity. Knockdown was recorded 60 mins after exposure and delayed mortality after 24 h for all treatments. The insecticide-treated filter papers were obtained from Universiti Sains Malaysia.

Experimental huts and treatment application

The experimental huts used for the trials were of standard West African design, made from concrete bricks with cement-plastered walls and ceiling and a corrugated iron roof. A wooden-framed veranda projects from the rear wall of each hut to capture mosquitoes exiting due to behavioural or

insecticidal effects. Each hut is constructed on a water-filled moat to preclude entry of predators and mosquito entry occurs via four window slits measuring 1 cm positioned on two sides of the hut.

Prior to the application of the IRS treatments, the IRS insecticide formulations were mixed with appropriate volumes of water to obtain insecticide solutions at desired concentrations. Interior hut walls and ceilings were sprayed from top to bottom by a trained spray team using a Hudson X-pert® compression sprayer equipped with a flat-fan nozzle. Spray swaths were pre-marked on hut walls and ceilings using chalk to improve the accuracy of spraying. To assess the quality of spray application, the spray tank was weighed before and after spraying to assess the volume of insecticide solution applied. All volumes of insecticide solution applied were within the $\pm 30\%$ acceptable deviation from the target, indicating that the treatments were applied correctly. Bed nets were erected over sleeping areas by tying the four corners of the roof panel to nails positioned at the four uppermost corners inside the hut. To simulate wear and tear from routine household use, each ITN received 6 holes each measuring 16 cm² cut into each side of the net.

Experimental hut trial procedure

During the hut trials, volunteer sleepers were rotated between experimental huts daily to mitigate the impact of individual attractiveness whilst bed nets were rotated weekly between the huts to reduce the impact of hut position on mosquito entry. Three (3) replicate bed nets were used per treatment and rotated within the treatment every 2 days. IRS treatments cannot be rotated and thus remained fixed throughout the trial. Consenting human volunteer sleepers slept in experimental huts between 21:00 and 06:00 to attract free-flying mosquitoes. Each morning, volunteer sleepers collected all live and dead mosquitoes from the different compartments of the hut (under the net, room, veranda) using a torch and aspirator and placed them in correspondingly labelled plastic cups. Mosquito collections were then transferred to the field laboratory for morphological identification using taxonomic keys and scoring of immediate mortality and blood-feeding. All live, female *An. gambiae* s.l. were provided access to 10% glucose (w/v) solution and held at ambient conditions in the field laboratory. Delayed mortality was recorded after 24 h for all treatments. Mosquito collections were performed 6 nights per week and on the 7th day, huts were cleaned and aired in preparation for the next rotation cycle.

Hut trial outcome measures

The efficacy of the experimental hut treatments was expressed in terms of the following outcome measures:

1. Deterrence (%) – proportional reduction in the number of mosquitoes collected in the treated hut relative to the number collected in the control.
2. Exophily (%) – exiting rates due to potential irritant effect of the treatment expressed as the proportion of mosquitoes collected in the veranda trap.
3. Blood-feeding inhibition (%) – proportional reduction in blood-feeding in the treated hut relative to the control. Calculated as follows:

$$\text{Bloodfeeding inhibition (\%)} = \frac{100(B_{fu} - B_{ft})}{B_{fu}}$$

Where B_{fu} is the number of blood-fed mosquitoes in the untreated net control huts and B_t is the number of mosquitoes in the huts with insecticide treatments.

4. Mortality (%) – proportion of dead mosquitoes 24 hours after collection.
5. Personal protection (%) – reduction in the number of blood-fed mosquitoes in the treated hut relative to the untreated net control. Calculated as follows:

$$\text{Personal protection (\%)} = \frac{100(B_u - B_t)}{B_u}$$

Where B_u is the number of blood-fed mosquitoes in the untreated net control huts and B_t is the number of mosquitoes in the huts with insecticide treatments.

Tunnel tests

The tunnel test consists of a square glass cylinder (25 cm high, 25 cm wide, 60 cm in length) divided into two sections using a netting frame fitted into a slot across the tunnel. In one of the sections, a guinea pig was housed unconstrained in a small cage, and in the other section, ~100 unfed female mosquitoes aged 5–8 days were released at dusk and left overnight. The net samples were deliberately holed with nine 1-cm holes to give opportunity for mosquitoes to penetrate the animal baited chamber for a blood meal; an untreated net sample served as the control. The tunnels were kept overnight in a dark room at 25–29°C and 65–85% RH. The next morning, the numbers of mosquitoes found alive or dead, fed or unfed, in each section were scored. Live mosquitoes were provided with 10% glucose solution and delayed mortality was recorded after 24 hours. The pyrethroid-PBO ITNs were compared to Olyset® Net (a permethrin-only net, Sumitomo chemical) and PermaNet® 2.0 (a deltamethrin-only net, Vestergaard Sarl) and an untreated control net. Two to three net pieces were tested per net type.

Wall cone bioassays

The laboratory-maintained, susceptible *An. gambiae* s.s. Kisumu strain and wild pyrethroid-resistant *An. gambiae* s.l. Covè mosquitoes (F1) derived from breeding sites at the hut station were used for this purpose. At each time point, five cones were attached to the walls and ceiling of the IRS-treated huts. Approximately 50, 3–5-day old mosquitoes were transferred into cones in 5 batches of 10 and exposed to the treated surfaces for 30 mins. As a control, mosquitoes were exposed in cones attached to the walls and ceiling of an unsprayed hut. At the end of exposure, mosquitoes were transferred to netted, plastic cups. Mosquitoes were provided access to 10% (w/v) glucose solution and delayed mortality after 24 h for all treatments.

Ethical considerations

Ethical approval for the conduct of the study was obtained from the ethics review boards of the Beninese Ministry of Health (Avis éthique No. 34) and the London School of Hygiene & Tropical Medicine (Ethics Ref: 16969). All human volunteer sleepers gave informed written consent prior to their participation; where necessary, the consent form and information sheet were explained in their local language. They were offered a free course of chemoprophylaxis spanning the duration of the trial and up to 3 weeks following its completion. A stand-by nurse was available for the duration of the trial to assess any cases of fever or adverse reactions to test items. Any confirmed cases of malaria were treated free of charge at a local health facility. Animals used as baits in tunnel tests were maintained following institutional standard operating procedures (SOPs) designed to improve

care and protect animals used for experimentation. All studies were performed according to relevant national and international guidelines.

Data analysis

Differences in proportional outcomes (exophily, blood-feeding, mortality) between experimental hut treatments were analysed using a blocked logistic regression model whereas differences in numerical outcomes (mosquito entry) were assessed using a negative binomial regression model. In addition to the fixed effect of the treatment, both models were adjusted to account for variation due to the differential attractiveness of the volunteer sleepers and huts. Results from the different experimental hut trials involving Olyset® Plus and PermaNet® 3.0 were analysed separately. Susceptibility bioassay results were interpreted according to WHO criteria [49]. All analyses were performed in Stata version 15.1.

References

1. Bhatt S, Weiss DJ, Cameron E, Bisanzio D, Mappin B, Dalrymple U, Battle KE, Moyes CL, Henry A, Eckhoff PA, et al: **The effect of malaria control on Plasmodium falciparum in Africa between 2000 and 2015.** *Nature* 2015, **526**:207-211.
2. WHO: **Global report on insecticide resistance in malaria vectors: 2010–2016.** Geneva, Switzerland: World Health Organization 2018.
3. WHO: **List of WHO prequalified vector control products.** Geneva, Switzerland: World Health Organization 2021, <https://www.who.int/pq-vector-control/prequalified-lists/PrequalifiedProducts27January2020.pdf?ua=1>.
4. Bingham G, Strode C, Tran L, Khoa PT, Jamet HP: **Can piperonyl butoxide enhance the efficacy of pyrethroids against pyrethroid-resistant Aedes aegypti?** *Trop Med Int Health* 2011, **16**:492-500.
5. WHO: **Conditions for deployment of mosquito nets treated with a pyrethroid and piperonyl butoxide.** Geneva, Switzerland: World Health Organization 2017.
6. Protopopoff N, Mosha JF, Lukole E, Charlwood JD, Wright A, Mwalimu CD, Manjurano A, Mosha FW, Kisinza W, Kleinschmidt I, Rowland M: **Effectiveness of a long-lasting piperonyl butoxide-treated insecticidal net and indoor residual spray interventions, separately and together, against malaria transmitted by pyrethroid-resistant mosquitoes: a cluster, randomised controlled, two-by-two factorial design trial.** *Lancet* 2018, **391**:1577-1588.
7. Staedke SG, Gonahasa S, Dorsey G, Kamya MR, Maiteki-Sebuguzi C, Lynd A, Katureebe A, Kyohere M, Mutungi P, Kigozi SP, et al: **Effect of long-lasting insecticidal nets with and without piperonyl butoxide on malaria indicators in Uganda (LLINEUP): a pragmatic, cluster-randomised trial embedded in a national LLIN distribution campaign.** *Lancet* 2020, **395**:1292-1303.
8. President's Malaria Initiative: **The U.S. President's Malaria Initiative Fourteenth Annual Report to Congress.** President's Malaria Initiative; 2020.
9. UNICEF: **Long-lasting insecticidal nets market and supply update.** UNICEF; 2020.
10. The Alliance for Malaria Prevention Net Mapping Project: **Global Delivery Report.** 2020.
11. WHO: **Global insecticide use for vector-borne disease control: a 10-year assessment (2010–2019), sixth edition.** World Health Organisation 2021, <https://apps.who.int/iris/bitstream/handle/10665/345573/9789240032033-eng.pdf>.

12. Tangena J-AA, Hendriks CMJ, Devine M, Tammamro M, Trett AE, Williams I, DePina AJ, Sisay A, Herizo R, Kafy HT, et al: **Indoor residual spraying for malaria control in sub-Saharan Africa 1997 to 2017: an adjusted retrospective analysis.** *Malaria Journal* 2020, **19**:150.
13. Oxborough RM: **Trends in US President's Malaria Initiative-funded indoor residual spray coverage and insecticide choice in sub-Saharan Africa (2008–2015): urgent need for affordable, long-lasting insecticides.** *Malaria journal* 2016, **15**:146.
14. Oxborough RM, Kitau J, Jones R, Feston E, Matowo J, Mosha FW, Rowland MW: **Long-lasting control of Anopheles arabiensis by a single spray application of micro-encapsulated pirimiphos-methyl (Actellic® 300 CS).** *Malaria journal* 2014, **13**:1-16.
15. Rowland M, Boko P, Odjo A, Asidi A, Akogbeto M, N'Guessan R: **A new long-lasting indoor residual formulation of the organophosphate insecticide pirimiphos methyl for prolonged control of pyrethroid-resistant mosquitoes: an experimental hut trial in Benin.** *PloS one* 2013, **8**:e69516.
16. Chaccour C, Zulliger R, Wagman J, Casellas A, Nacima A, Elobolobo E, Savaio B, Saifodine A, Fornadel C, Richardson J: **Incremental impact on malaria incidence following indoor residual spraying in a highly endemic area with high standard ITN access in Mozambique: results from a cluster-randomized study.** *Malaria journal* 2021, **20**:1-15.
17. Wagman JM, Varela K, Zulliger R, Saifodine A, Muthoni R, Magesa S, Chaccour C, Gogue C, Tynuv K, Seyoum A: **Reduced exposure to malaria vectors following indoor residual spraying of pirimiphos-methyl in a high-burden district of rural Mozambique with high ownership of long-lasting insecticidal nets: entomological surveillance results from a cluster-randomized trial.** *Malaria Journal* 2021, **20**:1-17.
18. Abong'o B, Gimnig JE, Torr SJ, Longman B, Omoke D, Muchoki M, Ter Kuile F, Ochomo E, Munga S, Samuels AM: **Impact of indoor residual spraying with pirimiphos-methyl (Actellic 300CS) on entomological indicators of transmission and malaria case burden in Migori County, western Kenya.** *Scientific reports* 2020, **10**:1-14.
19. Gogue C, Wagman J, Tynuv K, Saibu A, Yihdego Y, Malm K, Mohamed W, Akplu W, Tagoe T, Ofosu A: **An observational analysis of the impact of indoor residual spraying in Northern, Upper East, and Upper West Regions of Ghana: 2014 through 2017.** *Malaria Journal* 2020, **19**:1-13.
20. Wagman J, Cissé I, Kone D, Fomba S, Eckert E, Mihigo J, Bankineza E, Bah M, Diallo D, Gogue C: **Rapid reduction of malaria transmission following the introduction of indoor residual spraying in previously unsprayed districts: an observational analysis of Mopti Region, Mali, in 2017.** *Malaria Journal* 2020, **19**:1-10.
21. Salako AS, Dagnon F, Sovi A, Padonou GG, Aikpon R, Ahogni I, Syme T, Govoétchan R, Sagbohan H, Sominahouin AA: **Efficacy of Actellic 300 CS-based indoor residual spraying on key entomological indicators of malaria transmission in Alibori and Donga, two regions of northern Benin.** *Parasites & vectors* 2019, **12**:1-14.
22. Wagman J, Cissé I, Kone D, Fomba S, Eckert E, Mihigo J, Bankineza E, Bah M, Diallo D, Gogue C: **Combining next-generation indoor residual spraying and drug-based malaria control strategies: observational evidence of a combined effect in Mali.** *Malaria Journal* 2020, **19**:1-11.
23. Syme T, Fongnikin A, Todjinou D, Govoetchan R, Gbegbo M, Rowland M, Akogbeto M, Ngufor C: **Which indoor residual spraying insecticide best complements standard pyrethroid long-lasting insecticidal nets for improved control of pyrethroid resistant malaria vectors?** *PLoS One* 2021, **16**:e0245804.
24. Yunta C, Hemmings K, Stevenson B, Koekemoer LL, Matambo T, Pignatelli P, Voice M, Nász S, Paine MJ: **Cross-resistance profiles of malaria mosquito P450s associated with pyrethroid resistance against WHO insecticides.** *Pesticide biochemistry and physiology* 2019, **161**:61-67.

25. World Health Organisation: **Conditions for use of long-lasting insecticidal nets treated with a pyrethroid and piperonyl butoxide**. World Health Organisation; 2015.
26. Ankley GT, Dierkes JR, Jensen DA, Peterson GS: **Piperonyl butoxide as a tool in aquatic toxicological research with organophosphate insecticides**. *Ecotoxicology and environmental safety* 1991, **21**:266-274.
27. El-Merhibi A, Kumar A, Smeaton T: **Role of piperonyl butoxide in the toxicity of chlorpyrifos to *Ceriodaphnia dubia* and *Xenopus laevis***. *Ecotoxicology and environmental safety* 2004, **57**:202-212.
28. Yuan JZ, Li QF, Huang JB, Gao JF: **Effect of chlorfenapyr on cypermethrin-resistant *Culex pipiens pallens* Coq mosquitoes**. *Acta tropica* 2015, **143**:13-17.
29. Raghavendra K, Barik TK, Bhatt RM, Srivastava HC, Sreehari U, Dash AP: **Evaluation of the pyrrole insecticide chlorfenapyr for the control of *Culex quinquefasciatus* Say**. *Acta tropica* 2011, **118**:50-55.
30. Raghavendra K, Barik TK, Sharma P, Bhatt RM, Srivastava HC, Sreehari U, Dash AP: **Chlorfenapyr: a new insecticide with novel mode of action can control pyrethroid resistant malaria vectors**. *Malar J* 2011, **10**:16.
31. WHO: **Guidelines for testing mosquito adulticides for indoor residual spraying and treatment of mosquito nets**. World Health Organisation 2006, Geneva, Switzerland.
32. WHO: **Guidelines for laboratory and field testing of long-lasting insecticidal nets**. Geneva, Switzerland: World Health Organization 2013.
33. Ngufor C, N'Guessan R, Fagbohoun J, Subramaniam K, Odjo A, Fongnikin A, Akogbeto M, Weetman D, Rowland M: **Insecticide resistance profile of *Anopheles gambiae* from a phase II field station in Cote d'Ivoire, southern Benin: implications for the evaluation of novel vector control products**. *Malar J* 2015, **14**:464.
34. Gleave K, Lissenden N, Richardson M, Choi L, Ranson H: **Piperonyl butoxide (PBO) combined with pyrethroids in insecticide-treated nets to prevent malaria in Africa**. *Cochrane Database Syst Rev* 2018, **11**:CD012776.
35. N'Guessan R, Odjo A, Ngufor C, Malone D, Rowland M: **A Chlorfenapyr Mixture Net Interceptor(R) G2 Shows High Efficacy and Wash Durability against Resistant Mosquitoes in West Africa**. *PLoS One* 2016, **11**:e0165925.
36. Ngufor C, Fagbohoun J, Critchley J, N'Guessan R, Tadjinou D, Malone D, Akogbeto M, Rowland M: **Which intervention is better for malaria vector control: insecticide mixture long-lasting insecticidal nets or standard pyrethroid nets combined with indoor residual spraying?** *Malar J* 2017, **16**:340.
37. Bayili K, N'Do S, Yadav RS, Namountougou M, Ouattara A, Dabiré RK, Ouédraogo GA, Diabaté A: **Experimental hut evaluation of DawaPlus 3.0 LN and DawaPlus 4.0 LN treated with deltamethrin and PBO against free-flying populations of *Anopheles gambiae* s. l. in Vallée du Kou, Burkina Faso**. *PloS one* 2019, **14**:e0226191.
38. Menze BD, Kouamo MF, Wondji MJ, Tchagga W, Tchoupo M, Kusimo MO, Mouhamadou CS, Riveron JM, Wondji CS: **An experimental hut evaluation of PBO-based and pyrethroid-only nets against the malaria vector *Anopheles funestus* reveals a loss of bed nets efficacy associated with GSTe2 metabolic resistance**. *Genes* 2020, **11**:143.
39. Kouassi BL, Edi C, Tia E, Konan LY, Akre MA, Koffi AA, Ouattara AF, Tanoh AM, Zinzindohoue P, Kouadio B: **Susceptibility of *Anopheles gambiae* from Côte d'Ivoire to insecticides used on insecticide-treated nets: evaluating the additional entomological impact of piperonyl butoxide and chlorfenapyr**. *Malaria journal* 2020, **19**:1-11.
40. Cisse MB, Sangare D, Oxborough RM, Dicko A, Dengela D, Sadou A, Mihigo J, George K, Norris L, Fornadel C: **A village level cluster-randomized entomological evaluation of combination long-lasting insecticidal nets containing pyrethroid plus PBO synergist in Southern Mali**. *Malaria journal* 2017, **16**:1-11.

41. Hancock PA, Hendriks CJM, Tangena J-A, Gibson H, Hemingway J, Coleman M, Gething PW, Cameron E, Bhatt S, Moyes CL: **Mapping trends in insecticide resistance phenotypes in African malaria vectors.** *PLoS biology* 2020, **18**:e3000633-e3000633.
42. WHO: **Global Plan for Insecticide Resistance Management in Malaria Vectors.** . Geneva, Switzerland: World Health Organization 2012.
43. Matowo J, Kitau J, Kaaya R, Kavishe R, Wright A, Kisinza W, Kleinschmidt I, Mosha F, Rowland M, Protopopoff N: **Trends in the selection of insecticide resistance in *Anopheles gambiae* s.l. mosquitoes in northwest Tanzania during a community randomized trial of longlasting insecticidal nets and indoor residual spraying.** *Medical and veterinary entomology* 2015, **29**:51-59.
44. Grieco JP, Achee NL, Chareonviriyaphap T, Suwonkerd W, Chauhan K, Sardelis MR, Roberts DR: **A new classification system for the actions of IRS chemicals traditionally used for malaria control.** *PLoS one* 2007, **2**:e716.
45. Ngufor C, Critchley J, Fagbohoun J, N'Guessan R, Tadjinou D, Rowland M: **Chlorfenapyr (A Pyrrole Insecticide) Applied Alone or as a Mixture with Alpha-Cypermethrin for Indoor Residual Spraying against Pyrethroid Resistant *Anopheles gambiae* sl: An Experimental Hut Study in Cote d'Ivoire, Benin.** *PLoS One* 2016, **11**:e0162210.
46. Ngufor C, Fongnikin A, Hobbs N, Gbegbo M, Kiki L, Odjo A, Akogbeto M, Rowland M: **Indoor spraying with chlorfenapyr (a pyrrole insecticide) provides residual control of pyrethroid-resistant malaria vectors in southern Benin.** *Malaria Journal* 2020, **19**:249.
47. Oxborough RM, N'Guessan R, Jones R, Kitau J, Ngufor C, Malone D, Mosha FW, Rowland MW: **The activity of the pyrrole insecticide chlorfenapyr in mosquito bioassay: towards a more rational testing and screening of non-neurotoxic insecticides for malaria vector control.** *Malar J* 2015, **14**:124.
48. WHO: **Test procedures for insecticide resistance monitoring in malaria vector mosquitoes; second edition.** World Health Organisation 2016.
49. World Health Organisation: **Test procedures for insecticide resistance monitoring in malaria vector mosquitoes.** World Health Organisation; 2016.

Declarations

Consent for publication

Not applicable

Competing interests

The authors declare that they have no competing interests

Funding

CN was supported by the LSHTM Athena Swan restart fellowship. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.

Authors' contributions

TS supervised the experiments, analysed the data, and contributed to manuscript preparation. MG, DO, AA and AF conducted the experimental hut trials and tunnel tests. DT performed the resistance bioassays. CN designed the study, supervised the project, and prepared the final manuscript.

Acknowledgements

We thank the technical staff of CREC (Abibath Odjo, Josias Fagbohoun, Estelle Vigninou, Boris Ndombidje etc) for their assistance. We are grateful to the rice farmers at Covè for their support in the hut study.

Authors' information

Not applicable

List of abbreviations

IRS: Indoor Residual Spraying
 WHO: World Health Organization
 PQ: Prequalification team
 PBO: Piperonyl Butoxide
 ITN: Insecticide treated net
 LLIN: Long-lasting Insecticidal net
 GPIRM: Global Plan for Insecticide Resistance Management
 WHOPES: WHO Pesticide Evaluation Scheme
 CREC: Centre de Recherche Entomologique de Cotonou
 LSHTM: London School of Hygiene & Tropical Medicine
 Kdr: Knockdown resistance

Can pyrethroid-piperonyl butoxide (PBO) nets reduce the efficacy of indoor residual spraying with pirimiphos-methyl against pyrethroid-resistant malaria vectors?

Authors: Thomas Syme^{1,2,3}, Martial Gbegbo^{2,3}, Dorothy Obuobi^{1,2,3}, Augustin Fongnikin^{2,3}, Abel Agbevo^{2,3}, Damien Todjinou^{2,3}, Corine Ngufor^{1,2,3*}

Supplementary information

Table S1: Detailed results from tunnel tests with pyrethroid-PBO and pyrethroid-only nets

Strain	Susceptible <i>An. gambiae</i> Kisumu						Pyrethroid-resistant <i>An gambiae</i> s.l. Covè					
Net type	Untreated net	Olyset Net	PermaNet 2.0	Olyset Plus	PermaNet 3.0 (sides)	PermaNet 3.0 (roof)	Untreated net	Olyset Net	PermaNet 2.0	Olyset Plus	PermaNet 3.0 (sides)	PermaNet 3.0 (roof)
N exposed	307	191	218	191	196	229	208	300	216	303	184	200
N pass	236	65	44	11	58	109	107	69	59	53	103	108
% pass	76.9	34.0	20.2	5.8	29.6	47.6	51.4	23.0	27.3	17.5	56.0	54.0
95% CIs range	72.2-81.6	27.3-40.8	14.9-25.5	2.5-9.1	23.2-36	41.1-54.1	44.6-58.2	18.2-27.8	21.4-33.3	13.2-21.8	48.8-63.2	47.1-60.9
N blood fed	246.0	105.0	0.0	0.0	2.0	7.0	191.0	22.0	26.0	6.0	73.0	68.0
% blood fed	80.1	55.0	0.0	0.0	1.0	3.1	91.8	7.3	12.0	2.0	39.7	34.0
95% CIs range	75.7-84.6	47.9-62	0.0-5	0.0-5	0-2.4	0.8-5.3	88.1-95.6	4.4-10.3	7.7-16.4	0.4-3.6	32.6-46.7	27.4-40.6
% blood-feeding inhibition	-	31.4	100.0	100.0	98.7	96.2	-	92.0	86.9	97.8	56.8	63.0
N dead 24 h	34.0	187.0	218.0	190.0	196.0	227.0	5.0	125.0	58.0	272.0	62.0	136.0
% dead 24 h	11.1	97.9	100.0	99.5	100.0	99.1	2.4	41.7	26.9	89.8	33.7	68.0
95% CIs range	7.6-14.6	95.9-99.9	95-100.0	98.5-100.0	95-100.0	97.9-100.0	0.3-4.5	36.1-47.3	20.9-32.8	86.4-93.2	26.8-40.5	61.5-74.5